Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis

Authors :: Giovanni Adami
Giovanni Orsolini
Maurizio Rossini
Anna Fratucello
Angelo Fassio
Ombretta Viapiana
Elena Fracassi
Riccardo Bixio
Davide Gatti
Source :: BMC Rheumatology, Vol 8, Iss 1, Pp 1-10 (2024)
Publication Year :: 2024
Publisher :: BMC, 2024.
Abstract: Key-points Bone turnover makers (P1nP, B-ALP, CTX), bone modulators (Dkk1, sclerostin) and BMD were measured prospectively in rheumatoid arthritis patients treated with tofacitinib. Sclerostin increased significantly after treatment with tofacitinib, P1nP and B-ALP (markers of bone formation) decreased significantly.

Subjects :: Tofacitinib
Bone Mineral density (BMD)
Bone turnover markers (BTMs)
Bone metabolism inflammation
Diseases of the musculoskeletal system
RC925-935

Full Text Access

Tools